X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

Core Viewpoint - X4 Pharmaceuticals has initiated an underwritten public offering of its common stock and pre-funded warrants, aiming to raise funds for the development of mavorixafor and other corporate purposes [1][2]. Group 1: Offering Details - The public offering includes an option for underwriters to purchase an additional 15% of the shares offered at the public offering price [1]. - The offering is subject to market conditions, and there is no guarantee regarding its completion or the terms [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to the pivotal Phase 3 development of mavorixafor for chronic neutropenic disorders, as well as for general administrative expenses, capital expenditures, and working capital [2]. Group 3: Company Background - X4 Pharmaceuticals focuses on developing therapies for rare hematology diseases, with mavorixafor being a key product currently marketed in the U.S. as XOLREMDI® [5]. - The company is conducting a global pivotal Phase 3 clinical trial (4WARD) for mavorixafor in patients with chronic neutropenic disorders [5].